105 related articles for article (PubMed ID: 9632349)
1. Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
Ennis MD; Ghazal NB; Hoffman RL; Smith MW; Schlachter SK; Lawson CF; Im WB; Pregenzer JF; Svensson KA; Lewis RA; Hall ED; Sutter DM; Harris LT; McCall RB
J Med Chem; 1998 Jun; 41(13):2180-3. PubMed ID: 9632349
[No Abstract] [Full Text] [Related]
2. 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
Chambers MS; Street LJ; Goodacre S; Hobbs SC; Hunt P; Jelley RA; Matassa VG; Reeve AJ; Sternfeld F; Beer MS; Stanton JA; Rathbone D; Watt AP; MacLeod AM
J Med Chem; 1999 Feb; 42(4):691-705. PubMed ID: 10052976
[TBL] [Abstract][Full Text] [Related]
3. BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential.
Saxena PR; De Vries P; Heiligers JP; Bax WA; Maassen VanDenBrink A; Yocca FD
Eur J Pharmacol; 1998 Jun; 351(3):329-39. PubMed ID: 9721025
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
[TBL] [Abstract][Full Text] [Related]
5. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
[TBL] [Abstract][Full Text] [Related]
6. Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
MacLeod AM; Street LJ; Reeve AJ; Jelley RA; Sternfeld F; Beer MS; Stanton JA; Watt AP; Rathbone D; Matassa VG
J Med Chem; 1997 Oct; 40(22):3501-3. PubMed ID: 9357515
[No Abstract] [Full Text] [Related]
7. Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses.
De Vries P; Willems EW; Heiligers JP; Villalón CM; Saxena PR
Br J Pharmacol; 1999 May; 127(2):405-12. PubMed ID: 10385240
[TBL] [Abstract][Full Text] [Related]
8. Donitriptan (Pierre Fabre).
Dukat M
Curr Opin Investig Drugs; 2001 Mar; 2(3):415-8. PubMed ID: 11575714
[TBL] [Abstract][Full Text] [Related]
9. Present and future of 5-HT receptor agonists as antimigraine drugs.
Pauwels PJ; John GW
Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
[TBL] [Abstract][Full Text] [Related]
10. The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater.
Yu XJ; Cutrer FM; Moskowitz MA; Waeber C
Neuropharmacology; 1997 Jan; 36(1):83-91. PubMed ID: 9144644
[TBL] [Abstract][Full Text] [Related]
11. The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Petty MA; Elands J; Johnson MP; Linnik MD; Hamel E; Moskowitz MA; Lee WS; McCarty DR; Hibert M; Baron BM
Eur J Pharmacol; 1997 Oct; 336(2-3):127-36. PubMed ID: 9384224
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633.
McCall RB; Huff R; Chio CL; TenBrink R; Bergh CL; Ennis MD; Ghazal NB; Hoffman RL; Meisheri K; Higdon NR; Hall E
Cephalalgia; 2002 Dec; 22(10):799-806. PubMed ID: 12485205
[TBL] [Abstract][Full Text] [Related]
13. Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential.
Saxena PR; De Vries P; Wang W; Heiligers JP; Maassen vandenBrink A; Bax WA; Yocca FD
Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):295-302. PubMed ID: 9050026
[TBL] [Abstract][Full Text] [Related]
14. Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands).
Pregenzer JF; Alberts GL; Im WB; Slightom JL; Ennis MD; Hoffman RL; Ghazal NB; TenBrink RE
Br J Pharmacol; 1999 May; 127(2):468-72. PubMed ID: 10385247
[TBL] [Abstract][Full Text] [Related]
15. [Triptans in migraine: a comparative review of pharmacology, pharmacokinetics].
Kato K
No To Shinkei; 2004 Sep; 56(9):733-8. PubMed ID: 15552861
[No Abstract] [Full Text] [Related]
16. Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis.
Cutrer FM; Yu XJ; Ayata G; Moskowitz MA; Waeber C
Neuropharmacology; 1999 Jul; 38(7):1043-53. PubMed ID: 10428423
[TBL] [Abstract][Full Text] [Related]
17. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
[TBL] [Abstract][Full Text] [Related]
18. [The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks].
Stepień A
Pol Merkur Lekarski; 1999 Jun; 6(36):341-3. PubMed ID: 10481551
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of 5HT in migraine.
Buzzi MG
Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
[No Abstract] [Full Text] [Related]
20. The antimigraine agent alniditan selectively constricts porcine carotid arteriovenous anastomoses via 5-HT1B/1D receptors.
De Vries P; Willems EW; Heiligers JP; Villalón CM; Saxena PR
Eur J Pharmacol; 1998 Jun; 351(2):193-201. PubMed ID: 9687003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
